NEW YORK, NY -- (Marketwired) -- 03/07/16 -- Lion Biotechnologies, (NASDAQ: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that President and Chief Executive Officer, Elma Hawkins, PhD, will participate in the following upcoming conferences:
Cowen and Company 36th Annual Health Care Conference
Date: Wednesday, March 9, 2016
Location: Boston Marriott Copley Place, Boston, MA
Moffitt Cancer Center's Business of Biotech 2016
Date: Friday, March 18, 2016
Location: Moffitt Cancer Center, Tampa, FL
4th Annual Cell & Gene Investor Day
Date: Tuesday, March 22, 2016
Location: Metropolitan Club, New York City
About Lion Biotechnologies
Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for the treatment of patients with refractory metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center. For more information, please visit http://www.lionbio.com.
Forward Looking Statements
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties described in the Company's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations
Molly Henderson
212.946.4826
Source: Lion Biotechnologies, Inc.
Released March 7, 2016